Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials

JAMA

Volumn 279, Issue 2, 1998, Pages 125-129

  Preston, Sandra L ^a,b   Drusano, George L ^a   Berman, Adam L ^a   Fowler, Cynthia L ^c   Chow, Andrew T ^c   Dornseif, Bruce ^c   Reichl, Veronica ^c   Natarajan, Jaya ^c   Corrado, Michael ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY COLLEGE OF PHARMACY   (United States)

^c R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; SINUSITIS; SKIN DEFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

EID: 0032515386     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.2.125     Document Type: Article

References (17)

1. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal samplingstrategy and adaptive study design. Clin Pharmacol Ther. 1988;44:232-238.
2. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther. 1989; 45:636-641.
3. Yuen GJ, Drusano GL, Forrest A, Plaisance KI, Caplan ES. Prospective use of optimal sampling theory. Clin Pharmacol Ther. 1989;46:451-457.
4. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445-479.
5. Gitterman SR, Drusano GL, Egorin MJ, Standiford HC, and the Veterans Administration Clinical Trials Group. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther. 1990;48:161-167.
6. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. Appl Math Computation. 1991;45:143-157.
7. Preston SL, Drusano GL. Non-parametric expectation maximization (NPEM2) modeling of ganciclovir. J Clin Pharmacol. 1996;36:301-310.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
9. D'Argenio DZ, Schumitzky A. ADAPT II: A Program for Simulation, Identification, and Optimal Experimental Design: User Manual. Los Angeles: Biomedical Simulations Resource, University of Southern California, Los Angeles; 1992.
10. Goodwin AD, Gallis MH, Chow AT, Wong FA, Flor AC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1994;38:799-804.
11. Wong FA, Juzwin SJ, Flor AC. Rapid stereospecific high-performance liquid chromotographic determination of levofloxacin in human plasma and urine. J Pharm Biomed Anal. 1997;15:765-771.
12. Breiman L, Freidman J, Olshen R, Stone C. Classification and Regression Trees. Pacific Grove, Calif: Wadsworth; 1984.
13. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:165-175.
14. Child J, Mortiboy JM, Chow AT, Wise R. Openlabel crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother. 1995;39:2749-2751.
15. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
16. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993;37:483-490.
17. Blaser JB, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31: 1054-1060.